{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:25:46Z","timestamp":1784917546883,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clml.2024.08.006","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T19:08:40Z","timestamp":1724526520000},"page":"e50-e56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-0358","authenticated-orcid":false,"given":"Aamer","family":"Aleem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naila A.","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farjah","family":"Algahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Alkhudair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashail","family":"Alghafis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1334-6372","authenticated-orcid":false,"given":"Zafar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2434-820X","authenticated-orcid":false,"given":"Hajar Wan Zuki","family":"Siti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alahmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-0813","authenticated-orcid":false,"given":"Hind","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giamal","family":"Gmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-5803","authenticated-orcid":false,"given":"Mohsen","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Alhejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Alfayez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-9446","authenticated-orcid":false,"given":"Abdullah","family":"Alrajhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Marei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0648-3256","authenticated-orcid":false,"given":"Ahmed","family":"Alaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.08.006_bib0001","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.08.006_bib0002","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.08.006_bib0003","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.006_bib0004","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2024.08.006_bib0005","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"GIMEMA. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.08.006_bib0006","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2024.08.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20165","article-title":"Comparison of hepatotoxicity associated with new bcr-abl tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2024.08.006_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.580759","article-title":"Global, regional, and national burden of chronic myeloid leukemia, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"10","author":"Lin","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.08.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.47950","article-title":"Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia","volume":"6","author":"Winn","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2024.08.006_bib0010","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.08.006_bib0011","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.08.006_bib0012","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.08.006_bib0013","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.08.006_bib0014","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cas.13430","article-title":"Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation","volume":"109","author":"Kumagai","year":"2018","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.clml.2024.08.006_bib0015","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","article-title":"Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan","volume":"103","author":"Takahashi","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.08.006_bib0016","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10147-018-1368-2","article-title":"Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)","volume":"24","author":"Fujisawa","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.08.006_bib0017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.clml.2024.08.006_bib0018","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2024.08.006_bib0019","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.08.006_bib0020","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.19058","article-title":"Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study","volume":"203","author":"Perusini","year":"2023","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2024.08.006_bib0021","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.clml.2024.08.006_bib0022","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.18883","article-title":"Treatment-free remission after dasatinib in patients with chronic myeloid leukemia in chronic phase with deep molecular response: final 5-year analysis of DASFREE","volume":"202","author":"Shah","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.08.006_bib0023","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.2019003395","article-title":"Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML","volume":"135","author":"Gottschalk","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.08.006_bib0024","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1159\/000525935","article-title":"treatment-free remission in real-world chronic myeloid leukemia patients: insights from German hematology practices","volume":"145","author":"Dengler","year":"2022","journal-title":"Acta Haematol"},{"issue":"10","key":"10.1016\/j.clml.2024.08.006_bib0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-018-0125-0","article-title":"Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients","volume":"8","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.08.006_bib0026","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3109\/10428194.2013.831092","article-title":"Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience","volume":"55","author":"Benjamini","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.08.006_bib0027","article-title":"Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: a feasible option also in the real-life. A Campus CML Study","volume":"12","author":"Lurlo","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2024.08.006_bib0028","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.13983","article-title":"How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience","volume":"176","author":"Ferrero","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2024.08.006_bib0029","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2024.08.006_bib0030","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/cas.14518","article-title":"Silent NK\/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission (D-STOP)","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.clml.2024.08.006_bib0031","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/jcm13030779","article-title":"Grupo Espa\u00f1ol de Leucemia Mieloide Cr\u00f3nica (GELMC). e14a2 transcript favors treatment-free remission in chronic myeloid leukemia when associated with longer treatment with tyrosine kinase inhibitors and sustained deep molecular response","volume":"13","author":"Marc\u00e9","year":"2024","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.clml.2024.08.006_bib0032","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2024.08.006_bib0033","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s12185-019-02744-5","article-title":"Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: a systematic review and meta-analysis","volume":"110","author":"Kim","year":"2019","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.08.006_bib0034","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2024.08.006_bib0035","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","article-title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","volume":"35","author":"Hughes","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.08.006_bib0036","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic Myeloid Leukemia, Version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2024.08.006_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1172910","article-title":"Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China","volume":"13","author":"Cheng","year":"2023","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.08.006_bib0040","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","article-title":"Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia","volume":"102","author":"Geelen","year":"2017","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.clml.2024.08.006_bib0038","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/bloodadvances.2020001772","article-title":"Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission","volume":"4","author":"Rousselot","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2024.08.006_bib0039","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024003100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024003100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:39:13Z","timestamp":1736059153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024003100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2152265024003100"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.08.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}